盈利稳定+增长前景可期瑞银看好Elevance Health(ELV.US)涨53%

智通财经08-08

智通财经APP获悉，在医疗保健公司Elevance Health(ELV.US)公布第二季度财报后，瑞银重申了对该股的“买入”评级，目标价为435美元。这一目标价较该股周四收盘价283.48美元有近53%的上涨空间。瑞银看好Elevance Health的理由是其盈利稳定性与增长前景。财报显示，Elevance Health Q2营收为498亿美元，好于市场预期;调整后每股收益为8.84美元，符合...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557462705?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-08 15:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557462705","market":"sh","top_or_hot":-1,"title":"盈利稳定+增长前景可期 瑞银看好Elevance Health(ELV.US)涨53%","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，在医疗保健公司Elevance Health(ELV.US)公布第二季度财报后，瑞银重申了对该股的“买入”评级，目标价为435美元。这一目标价较该股周四收盘价283.48美元有近53%的上涨空间。瑞银看好Elevance Health的理由是其盈利稳定性与增长前景。财报显示，Elevance Health Q2营收为498亿美元，好于市场预期;调整后每股收益为8.84美元，符合...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1327274.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>盈利稳定+增长前景可期 瑞银看好Elevance Health(ELV.US)涨53%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n盈利稳定+增长前景可期 瑞银看好Elevance Health(ELV.US)涨53%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-08 15:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1327274.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，在医疗保健公司Elevance Health(ELV.US)公布第二季度财报后，瑞银重申了对该股的“买入”评级，目标价为435美元。这一目标价较该股周四收盘价283.48美元有近53%的上涨空间。瑞银看好Elevance Health的理由是其盈利稳定性与增长前景。财报显示，Elevance Health Q2营收为498亿美元，好于市场预期;调整后每股收益为8.84美元，符合...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1327274.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0957791311.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1327274.html","article_id":"2557462705","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557462705","pubTimestamp":1754639841,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，在医疗保健公司Elevance Health公布第二季度财报后，瑞银重申了对该股的“买入”评级，目标价为435美元。瑞银看好Elevance Health的理由是其盈利稳定性与增长前景。财报显示，Elevance Health Q2营收为498亿美元，好于市场预期;调整后每股收益为8.84美元，符合市场预期。瑞银表示，Elevance Health上调医疗赔付率预期归因于《平价医疗法案》交易和医疗补助业务中成本趋势较预期更为不利。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","LU1815333072.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"AUP\" (USD) INC","ELV":"Elevance Health","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0882574055.USD":"富达全球健康医疗A ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","SG9999001077.SGD":"United International Growth Fund SGD","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0061474960.USD":"天利环球焦点基金AU Acc","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK4154":"管理型保健护理","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC"},"translate_title":"Stable earnings + promising growth prospects UBS is optimistic about Elevance Health (ELV.US) rising 53%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELV":1},"content_text":"智通财经APP获悉，在医疗保健公司Elevance Health(ELV.US)公布第二季度财报后，瑞银重申了对该股的“买入”评级，目标价为435美元。这一目标价较该股周四收盘价283.48美元有近53%的上涨空间。瑞银看好Elevance Health的理由是其盈利稳定性与增长前景。财报显示，Elevance Health Q2营收为498亿美元，好于市场预期;调整后每股收益为8.84美元，符合市场预期。不过，该公司将全年每股收益预期下调了4.50美元，相当于税前利润减少13亿美元。该公司还将2025年的医疗赔付率预期上调了90个基点。瑞银表示，Elevance Health上调医疗赔付率预期归因于《平价医疗法案》(ACA)交易和医疗补助业务中成本趋势较预期更为不利。不过，瑞银补充称，尽管如此，考虑到商业保险与Carelon业务板块的潜在盈利稳定性与增长空间，仍维持对该股的“买入”评级。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557462705","isCrawlerRequest":true}

盈利稳定+增长前景可期 瑞银看好Elevance Health(ELV.US)涨53%

精彩评论

盈利稳定+增长前景可期瑞银看好Elevance Health(ELV.US)涨53%